Key clinical point: The anti-IgE monoclonal antibody controlled hives and other symptoms well for up to a year.
Major finding: About 75% of the cohort experienced complete disease control at least once during the study.
Study details: The extension study comprised 96 patients treated with ligelizumab for 12 weeks in a phase 2 study.
Disclosures: Dr. Baker is a clinical trials investigator for Novartis, which is developing ligelizumab.
Baker D et al. AAD 2019,.